Announced Sat, 11 Apr · 12:20 IST

Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

MEDPLUS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.0%1-day move
₹867.00
prior close
₹849.05
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.4+1.0+1.1+1.1+0.0+0.2+1.4-0.0+0.9+5.5+2.8+3.1+0.3-5.4
Up moveDown movePending
AI summary

Optival Health Solutions Private Limited, a subsidiary of Medplus Health Services, received a suspension order from the Dy. Drugs Controller, Southern Zone, Berhmpur, Odisha. The drug license for one store located at Bahadur Bagicha pada, Odisha has been suspended for five days. The suspension is under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. The company disclosed a potential revenue loss of Rs 3.80 lakhs due to this suspension. The order was received on April 10, 2026.

Likely market impact

The impact on Medplus is minimal as it involves only one store out of the company's broader network, with a relatively small quantified revenue exposure of Rs 3.80 lakhs. This is a routine regulatory compliance matter and unlikely to have material impact on the stock.